ReviewHandbook of experimental pharmacology2026
Are the Direct Oral Anticoagulants Better Than Warfarin for the Prevention and Treatment of Stroke and Atrial Fibrillation?
Review in Handbook of experimental pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation is the most common cardiac arrhythmia in adults, affecting approximately 59.7 million people worldwide as of 2019-a 111% increase since 1990. Over the past 20 years, the prevalence of AF has risen by 33%, and it is projected to increase by more than 60% by 2050. Age plays a critical role in the factors that contribute to AF. Its prevalence is low (0.1%) in adults under 55 years old but rises to 5.9% in individuals aged 65 and older and 9.0% in those aged 80 and older. In this chapter, we provide a brief history of vitamin K antagonists and direct oral anticoagulants, both of which play a paramount role in atrial fibrillation. We also review the main differences between these two classes of anticoagulants. Furthermore, we aim to address the most common issues associated with DOACs use, particularly concerning patients with renal failure, obesity, and elderly or frail individuals. Lastly, we will discuss some remarks on randomized controlled trials and their limitations. The pivotal role of anticoagulation clinics is also highlighted here, underscoring the need for regular follow-up of both VKAs and DOACs.
Indexed as
Identifiers
41649510What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.